In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 ...
A recent study by UW researchers found that the 2019 “Hep C Free Washington” initiative was correlated with a decrease in the ...
Please provide your email address to receive an email when new articles are posted on . Chronic HCV infection was associated with a 1.8-fold increased risk for pancreatic ductal adenocarcinoma.
Hepatitis C virus screening rates in pregnancy increased from 2014 to 2024 but remained below universal screening recommendations.
Oral treatments with direct-acting antiviral medication have been a game-changer. These were approved in Ireland in late 2014 ...
Ruzasvir has demonstrated highly potent and pan-genotypic antiviral activity in preclinical (picomolar range) and clinical studies. Ruzasvir has been administered to over 2,800 HCV-infected patients ...
In the wake of recent breakthroughs in the management of hepatitis C virus (HCV) infection, with several new promising medications available on the market and more being studied in clinical trials, it ...
Occult HCV and HBV infections are recently identified entities whose existence became evident when nucleic acid amplification assays of enhanced sensitivity were employed for the detection of viral ...
Hepatitis C is a viral infection that affects your liver. You may not have symptoms. Hepatitis C is a viral infection caused by the hepatitis C virus (HCV) that affects the liver. It can be acute or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results